Pamukcu Rifat 4
4 · Aprea Therapeutics, Inc. · Filed Aug 24, 2023
Insider Transaction Report
Form 4
Pamukcu Rifat
Director
Transactions
- Award
Stock Options (Right to Buy)
2023-08-23+2,000→ 2,000 totalExercise: $3.65Exp: 2033-08-23→ Common Stock (2,000 underlying) - Award
Common Stock
2023-08-23+500→ 3,356 total - Conversion
Series A Non-Voting Convertible Preferred Stock
2022-08-23−4,928→ 0 totalExercise: $0.00→ Common Stock (49,280 underlying) - Conversion
Common Stock
2022-08-23+49,280→ 57,142 total - Conversion
Common Stock
2022-08-23+271,870→ 14,108 total(indirect: By LLC) - Conversion
Series A Non-Voting Convertible Preferred Stock
2022-08-23−27,187→ 0 total(indirect: By LLC)Exercise: $0.00→ Common Stock (271,870 underlying)
Footnotes (5)
- [F1]Following stockholder approval at the Issuer's annual stockholder's meeting, each share of Series A Non-Voting Convertible Preferred Stock is convertible into 10 shares of the Issuer's common stock ("Common Stock") at any time at the option of the holder thereof, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Series A Non-Voting Convertible Preferred Stock has no expiration date.
- [F2]These shares represent restricted stock units which were granted on August 23, 2023, and which will vest and be settled in common stock on August 23, 2024, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
- [F3]Reflects a one-for-20 reverse split, effective as of 5:00 p.m. Eastern Time on February 10, 2023
- [F4]The Reporting Person serves as Manager Partner of ZNZ Holdings L.L.C.
- [F5]The option vests in full on August 23, 2024, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.